Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Phase 4 Recruiting 39 enrolled Guangdong Provincial People's Hospital

NaSingle-groupOpen-labelTreatment

Summary

Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Timeline

Start: 2024-08-10
Primary completion: 2027-07-20
Completion: 2028-07-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	—

Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Summary

Timeline

Drugs

Indications